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Peritoneal macrophages  from  nonimmunized mice  become  specifically  cytotoxic 
after  incubation with  either  immune lymphoid cells  (1)  or  cell-free  supernatants 
from  cultures consisting of  sensitized lymphoid cells  and specific  target  cells  (2). 
Similar  supernatants  also  rendered  glass-adherent  bone  marrow  cells  specifically 
cytotoxic  (8).  Experiments described  in this  report  show  that  these  supernatants 
contain a  specific macrophage-arming factor (SMAF) whose  molecular weight indi- 
cates that it is too small to be an intact immunoglobulin,  yet at the same time has a 
specific recognition site for the target cell. In these experiments, immune reactions are 
probably directed against normal transplantation antigens since the mice were im- 
munized with allogeneic target cells.  However, parallel studies in purely syngeneic 
combinations where the antigenic disparity consists only of  tumor-specific antigens 
reveal that the properties of SMAF produced in the syngeneic system are very similar 
to those of SMAF produced in the allogeneic. 
The  design of  these  experiments is  intended to  demonstrate  that  SMAF 
production  is  dependent  on  the  presence  of  thymus-derived lymphoid  cells 
(T cells). 
Materials and Methods 
Mice.--Pure line CBA, DBA/2, and C57/BL mice 8-10 wk of age were used. 
Tumors.--The  SL2  and TLX9  lymphomas,  syngeneic for  DBA/2  and C57/BL  mice, 
respectively, grow as peritoneal ascites tumors. Their origin has been reported elsewhere (3). 
Cells used for immunization purposes or growth in cultures were aspirated from the peritoneal 
cavity 7 days after implantation  and washed three times in Fischer's medium. 
Cell Cultures.--(a)  Lymphoma  cells were seeded in growth  medium, Fischer's  medium 
containing 10-15% heat-inactivated  fetal bovine serum, at a concentration of 105 cells/ml. 
The generation time of SL2 is 13-16 hr, that of TLX9 is currently 24 hr. (b) Peritoneal macro- 
phage monolayers were prepared as described fully elsewhere (1). Approximately 1.6 >(  106 
macrophages in growth  medium were seeded into 3-cm Sterilin  dishes. (c)  Spleens were 
removed from immune or nonimmune CBA mice and cell suspensions were prepared by the 
method of Denham et al. (4). 
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Immunization.--CBA  mice were injected  intraperitoneally with  5  X  106  dividing SL2 
or TLX9 cells. Mice thymectomized at 10 wk of age, irradiated, and reconstituted with bone 
marrow cells  (5) were kindly supplied by Dr. A. J. S. Davies of this Institute. These T  cell- 
deprived mice could not reject a  challenge of dividing lymphoma cells and were immunized 
with two injections of 5  X  106 irradiated  (5000  R)  lymphoma cells 10 days  apart.  Sham- 
operated CBA mice, that is mice which received a "sham" thymectomy operation and were 
irradiated and reconstituted, were similarly treated.  Spleens were removed from immunized 
mice 14 days after the final immunization. 
Anti-O Serum.--The method used was a modification of that reported by Reif and Allen (6). 
AKR mice received four intraperitoneal injections of 2 )<  107 C3H thymocytes separated by 
3-wk intervals,  the first being given in conjunction with ttemophilus  pertussis vaccine (109 
organisms per mouse) as an adjuvant. Blood was collected from the axilla  14 days after the 
final injection, pooled, and the serum separated. This antiserum was cytotoxic in the presence 
of 1/10 complement (New Zealand White rabbit serum, absorbed with packed SL2 cells)  to 
mouse thymocytes and to 30% of spleen cells. Neither normal nor immune peritoneal macro- 
phages were affected by this treatment. 
Production of SMAF  by Immune  Spleen  Cells.--Cultures  of spleen  cells and  irradiated 
lymphoma  cells were prepared  (107 spleen cells:105 lymphoma cells per milliliter) and  in- 
cubated for 24 hr at 37°C (2). At this time the culture fluids were removed, centrifuged, and 
tested for their ability to render nonimmune CBA macrophages cytotoxic to target cells in an 
immunologically specific  manner  (see  below). 
Fractionation of SMAF.--Culture  supernatants  were concentrated  in  an  Amicon ultra- 
filtration cell (Amicon Corp., Lexington,  Mass.) using a 1)M.10 membrane, and 1 ml of con- 
centrate was placed on a Bio-Gel  A 0.5 M agarose gel column. The excluded  material  (F1), 
tool wt  >300,000, was concentrated and dialyzed, while the fractions eluted  after this were 
pooled and concentrated to 1.5 ml. 1 ml was then placed on a Bio-Gel 1)-150 polyacrylamide 
gel column. The eluate from this column was divided into three main fractions  corresponding 
to  molecular weight sizes  of  approximately  100-300,000  (F2),  50-100,000  (F3),  and  20- 
50,000 (F4) daltons, respectively. The fractions were dialyzed and reconstituted with Fischer's 
medium free of serum. 
Macrophage Cytotoxicity Test.--This test is based on the capacity of macrophage monolayers 
treated with SMAF to prevent growth of target cells. The reaction involves initially a cyto- 
static mechanism whereby target cells fail to divide, and this is followed by their death and 
disintegration. Cell-to-cell contact is required but phagocytosis of intact cells is not seen and 
occurs only when cells are disintegrating. The technique and method of assessing growth inhibi- 
tion is described fully elsewhere (1). 
RESULTS 
To demonstrate that SMAF possesses a  specific recognition site for the target 
cell  as  well  as  a  cytophilic  moiety  for  macrophages  (2),  SL2  or  TLX9  cells 
were  incubated  with  SMAF  produced  by  stimulation  of  spleens  from  specifi- 
cally immunized  CBA  mice,  and  also  with  SMAF  directed  against  the  unre- 
lated  target  cells. Table  I  shows that  target  cells treated  with SMAF  directed 
against  them  failed  to  grow  in  the  presence  of  macrophages,  whereas  target 
cells incubated  with  unrelated  SMAF  (i.e.  SL2  cells  treated  with  SMAF  di- 
rected  against  TLX9  cells)  glew normally.  SMAF  did not affect growth  of the 
specific  target  cells  in  the  absence  of  macrophages.  SMAF  could  be  totally 
absorbed  out by specific target  cells but  not by unrelated  cells. The cytophilic 
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SMAF directed against SL2 cells was fractionated, as described in Materials 
and Methods,  and four main fractions  (FI-F4)  were collected.  Serial fivefold 
dilutions of each fraction were prepared in growth medium and SL2 and TLX9 
cells were incubated with each dilution  for  1 hr  at 37°C.  The cells were then 
TABLE  I 
Growth  Inhibition of SL2  or  TLX9  Cells  after Incubation  with Supematants from  Immune 
Spleen Cell  Cultures with or without Target Cells 
Culture supernatant obtained from 
Percentage growth inhibition of lymphoma cells 48 hr 
after treatment with the various supernatants and 
seeding onto macrophage monolayers* 
SL2  TLX9 
%  % 
Spleen cells from CBA mice immunized with SL2 cells 
and then incubated with 
Irradiated SL2 cells  88  :k 5  4 
Irradiated TLX9 cells  8  6 
No ceils added  2  3 
Spleen cells from CBA mice immunized with TLX9 ceils 
and then incubated with 
Irradiated TLX9 cells  5  86  4-  8 
Irradiated SL2 cells  5  2 
No cells added  2  4 
* The lymphoma target cells were incubated at 106 cells/ml of supernatant for I hr at 37°C,  washed 3 X, and 
resuspended in growth medium. 3 ml containing 105 cells were added  to dishes with or without macrophages. 
Control cultures consisted of treated and untreated target cells grown in the absence of macrophages, or untreated 
ceils added to normal mactophage monolayers. In all of these,  SL2 cells grew to 1.5  X  10s 4- 10%;  TLX9 grew 
to 0.5  X  10' 4.  10%  over the 48 hr period. 
TABLE  II 
The F~ect of T  Cell  Deprivation  by Anti-O Serum  and Adult  Thymectomy  and  Whole Body 
Irradiation on the Ability of Immune Spleen Cells to Produce SMAF 
Macrophages incubated with supernatants produced by 
immune spleens (+ SL2 cells) from  No. of SL2 cells (X  106) at 48 hr 
Control immunized mice  0.2  4-  0.2  (87%) 
"  "  +  treated with anti-0 serum*  1.4  4.  0.2  (1%) 
Control unimmunized mice  1.5  4-  0.1 
"  +  treated with anti-0  1.4 :k  0.1 
serum 
T  cell-deprived mice  1.3  4-  0.1  (14%)§ 
Sham-operated mice++  0.5  4-  0.1  (67%) 
* Spleen cells treated with anti-0 serum before the addition of SL2 cells. 
:~ Whole body irradiated and reconstituted with bone marrow but not thymectomized. 
§ Growth  inhibition after  seeding  10  5 cells  per  monolayer. 
washed  thoroughly  and  placed  on  macrophage  monolayers  to  see  whether 
they grew or not. The data from numerous experiments indicated  that SMAF 
contains two major peaks of activity, the one containing material of molecular 
weight  greater  than  300,000  (F1),  the  other  between  50  and  100,000  (F3). 
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When  the  individual  tubes comprising  the  pooled F3  fraction were  titrated, 
the SMAF activity was found to be associated with a molecular weight size of 
50-60,000. 
The involvement of T  cells in  the production of SMAF  was shown in  two 
ways (see Table II): firstly, immune spleen cells exposed to anti-0 serum and 
complement did not produce SMAF on exposure to specific target cells,  while 
spleen cells not exposed to  anti-0  gave a  positive response to stimulation by 
target cells.  Secondly, SMAF could not be obtained from spleens of CBA mice 
which had been thymectomized, irradiated,  reconstituted with bone marrow, 
and immunized with two injections of irradiated SL2 cells (Table II). However, 
spleen cells from control sham-operated mice produced SMAF  in response to 
stimulation with specific target cells.  T  cell-deprived mice after immunization 
produced cytotoxic antiserum but no cytotoxic lymphocytes, macrophages, or 
arming  spleen  cells,  while  sham-operated  mice  produced  not  only cytotoxic 
serum but also cytotoxic lymphocytes, macrophages, and  arming spleen cells 
(data to be published). 
DISCUSSION 
A plethora of biologically active substances are released when lymphocytes 
from immunized donors are stimulated with specific antigens. These so-called 
lymphokines have been considered to be a product of the T  cells derived from 
the immunized animals (7). The present study would support this contention, 
that under conditions where one would expect lymphokines to be produced, a 
population of T  cells is required for the formation of SMAF.  On  fractionation 
SMAF  appears to consist of two major components, the one being >300,000 
daltons,  the other 50-60,000 daltons. Both have been shown to bind  (a) in a 
specific manner to the target cells used to sensitize the host and (b) in a totally 
nonspecific manner to mouse and rat peritoneal macrophages. Studies are now 
in progress to determine if the antigen recognition site of SMAF is similar to 
that of immunoglobulins and whether SMAF has determinants, peIhaps those 
of a light chain, which cross-react with known immunoglobulins. Previously (8) 
we had found that  a  SMAF-like material could be obtained when cells from 
the thymus of immunized mice were cultured with specific target cells.  These 
thymus cells were not cytotoxic and this suggests that the capacity to make 
SMAF  is  not  necessarily associated  with  a  population of T  cells which  are 
cytotoxic, although in spleen and lymph nodes there is another class of T  cells 
which is directly cytotoxic towards specific target cells. A similar situation has 
been encountered in mice immunized with syngeneic lymphoma cells in which 
the  lymphoid  cells which  were not  directly cytotoxic in  vitro  (9)  produced 
SMAF  (2). The relationship of SMAF to the immunologically specific macro- 
phage migration factor described by Amos and Lachmann  (10)  and  to  some 
other immunologically specific T  cell products discussed by Mitchison  et  al. 
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SUMMARY 
Spleen  cells  from mice immunized  with  an  allogeneic  tumor when  cultured 
with the specific tumor cells release into the supernatant  a specific maerophage- 
arming  factor(s)  (SMAF)  which  binds  nonspeeifically  to  macrophages  from 
both  mice  and  rats  and  renders  these  cytoto×ic  to  the  specific  tumor  cells. 
SMAF also binds in an immunologically specific way to the target cells. SMAF- 
treated  target  cells  grow  normally  in  the  absence  of  macrophages  but  are 
killed in the presence of normal macrophages. Thymus-derived cells are neces- 
sary for the production of SMAF  since  (a)  afte~  treatment  with  anti-0  serum 
immune  spleen  cells  fail  to  release  SMAF;  (b)  spleen  cells  flora  immunized 
T  cell-deprived  mice  (thymectomized  as  adults  followed  by  whole  body  ir- 
radiation  and  restored  with  bone  marrow)  fail  to  produce  SMAF on stimu- 
lation with the specific target cells. While SMAF has the properties of a  cyto- 
philic antibody, it does not belong to one of the established  classes of immuno- 
globulin since high activity is found after column separation in a fraction having 
a  molecular weight between 50,000-60,000 daltons. 
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